184 related articles for article (PubMed ID: 32436191)
21. Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2.
Prat A; Brase JC; Cheng Y; Nuciforo P; Paré L; Pascual T; Martínez D; Galván P; Vidal M; Adamo B; Hortobagyi GN; Baselga J; Ciruelos E
Oncologist; 2019 Jul; 24(7):893-900. PubMed ID: 30679318
[TBL] [Abstract][Full Text] [Related]
22. Clinical Impact of Tumor DNA Repair Expression and T-cell Infiltration in Breast Cancers.
Green AR; Aleskandarany MA; Ali R; Hodgson EG; Atabani S; De Souza K; Rakha EA; Ellis IO; Madhusudan S
Cancer Immunol Res; 2017 Apr; 5(4):292-299. PubMed ID: 28254786
[TBL] [Abstract][Full Text] [Related]
23. Ki-67 is a prognostic marker for hormone receptor positive tumors.
Pérez-López ME; García-Gómez J; Alves MT; Paradela A; García-Mata J; García-Caballero T
Clin Transl Oncol; 2016 Oct; 18(10):996-1002. PubMed ID: 26742937
[TBL] [Abstract][Full Text] [Related]
24. Estrogen receptor (ER) mRNA expression and molecular subtype distribution in ER-negative/progesterone receptor-positive breast cancers.
Itoh M; Iwamoto T; Matsuoka J; Nogami T; Motoki T; Shien T; Taira N; Niikura N; Hayashi N; Ohtani S; Higaki K; Fujiwara T; Doihara H; Symmans WF; Pusztai L
Breast Cancer Res Treat; 2014 Jan; 143(2):403-9. PubMed ID: 24337596
[TBL] [Abstract][Full Text] [Related]
25. Association of Histopathological Markers with Clinico- Pathological Factors in Mexican Women with Breast Cancer.
Bandala C; De la Garza-Montano P; Cortes-Algara A; Cruz-Lopez J; Dominguez-Rubio R; Gonzalez-Lopez JN; Cardenas-Rodriguez N; Alfaro-Rodriguez A; Salcedo M; Floriano-Sanchez E; Lara-Padilla E
Asian Pac J Cancer Prev; 2015; 16(18):8397-403. PubMed ID: 26745092
[TBL] [Abstract][Full Text] [Related]
26. A novel morphologic-molecular recurrence predictive model refines traditional prognostic tools for invasive breast carcinoma.
Ni YB; Tsang JY; Chan SK; Tse GM
Ann Surg Oncol; 2014 Sep; 21(9):2928-33. PubMed ID: 24743910
[TBL] [Abstract][Full Text] [Related]
27. Comparison of ER, PR and HER-2/neu (C-erb B 2) reactivity pattern with histologic grade, tumor size and lymph node status in breast cancer.
Azizun-Nisa ; Bhurgri Y; Raza F; Kayani N
Asian Pac J Cancer Prev; 2008; 9(4):553-6. PubMed ID: 19256737
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of the prognostic stage in the 8th edition of the American Joint Committee on Cancer in locally advanced breast cancer: An analysis based on SEER 18 database.
Wang M; Chen H; Wu K; Ding A; Zhang M; Zhang P
Breast; 2018 Feb; 37():56-63. PubMed ID: 29100045
[TBL] [Abstract][Full Text] [Related]
29. Back to Basics: Traditional Nottingham Grade Mitotic Counts Alone are Significant in Predicting Survival in Invasive Breast Carcinoma.
Chang JM; McCullough AE; Dueck AC; Kosiorek HE; Ocal IT; Lidner TK; Gray RJ; Wasif N; Northfelt DW; Anderson KS; Pockaj BA
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S509-15. PubMed ID: 26001860
[TBL] [Abstract][Full Text] [Related]
30. Identification of subtypes in human epidermal growth factor receptor 2--positive breast cancer reveals a gene signature prognostic of outcome.
Staaf J; Ringnér M; Vallon-Christersson J; Jönsson G; Bendahl PO; Holm K; Arason A; Gunnarsson H; Hegardt C; Agnarsson BA; Luts L; Grabau D; Fernö M; Malmström PO; Johannsson OT; Loman N; Barkardottir RB; Borg A
J Clin Oncol; 2010 Apr; 28(11):1813-20. PubMed ID: 20231686
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of the Incorporation of Recurrence Score into the American Joint Committee on Cancer Eighth Edition Staging System in Patients with T1-2N0M0, Estrogen Receptor-Positive, Human Epidermal Growth Receptor 2-Negative Invasive Breast Cancer: A Population-Based Analysis.
Ding S; Wu J; Lin C; Andriani L; Goh C; Chen W; Li Y; Shen K; Zhu L
Oncologist; 2019 Nov; 24(11):e1014-e1023. PubMed ID: 31019021
[TBL] [Abstract][Full Text] [Related]
32. Expression of Myxovirus Resistance A (MxA) Is Associated with Tumor-Infiltrating Lymphocytes in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancers.
Lee SJ; Hwang CS; Kim YK; Lee HJ; Ahn SJ; Shin N; Lee JH; Shin DH; Choi KU; Park DY; Lee CH; Huh GY; Sol MY; Lee HJ; Gong G; Kim JY; Kim A
Cancer Res Treat; 2017 Apr; 49(2):313-321. PubMed ID: 27456948
[TBL] [Abstract][Full Text] [Related]
33. Response of Triple Negative Breast Cancer to Neoadjuvant Chemotherapy: Correlation between Ki-67 Expression and Pathological Response.
Elnemr GM; El-Rashidy AH; Osman AH; Issa LF; Abbas OA; Al-Zahrani AS; El-Seman SM; Mohammed AA; Hassan AA
Asian Pac J Cancer Prev; 2016; 17(2):807-13. PubMed ID: 26925684
[TBL] [Abstract][Full Text] [Related]
34. [Effect of neoadjuvant chemotherapy on histologic grade and expression of biological markers in breast cancer].
Yin HF; Wang YH; Qin XQ; Zhang H; Li T; Ye JM; Liu YH
Zhonghua Zhong Liu Za Zhi; 2009 Nov; 31(11):858-62. PubMed ID: 20137353
[TBL] [Abstract][Full Text] [Related]
35. Vitamin D deficiency is associated with poor breast cancer prognostic features in postmenopausal women.
de Sousa Almeida-Filho B; De Luca Vespoli H; Pessoa EC; Machado M; Nahas-Neto J; Nahas EAP
J Steroid Biochem Mol Biol; 2017 Nov; 174():284-289. PubMed ID: 29031688
[TBL] [Abstract][Full Text] [Related]
36. Correlation of astrocyte elevated gene-1, basic-fibroblast growth factor, beta-catenin, Ki-67, tumor necrosis factor-alfa with prognostic parameters in ductal carcinomas and ductal intraepithelial neoplasms.
Erdem H; Gundogdu B; Ankarali H; Yasar M; Sener E; Oktay M; Bahadir A; Uzunlar AK; Gursan N; Ozaydin I; Sahiner C
Niger J Clin Pract; 2015; 18(5):638-43. PubMed ID: 26096243
[TBL] [Abstract][Full Text] [Related]
37. Traditional and new prognosticators in breast cancer: Nottingham index, Mib-1 and estrogen receptor signaling remain the best predictors of relapse and survival in a series of 289 cases.
Megha T; Neri A; Malagnino V; Caruso S; Onorati M; Roviello F; Tosi P
Cancer Biol Ther; 2010 Feb; 9(4):266-73. PubMed ID: 20026902
[TBL] [Abstract][Full Text] [Related]
38. Topoisomerase II alpha expression and the Ki-67 labeling index correlate with prognostic factors in estrogen receptor-positive and human epidermal growth factor type-2-negative breast cancer.
Tokiniwa H; Horiguchi J; Takata D; Kikuchi M; Rokutanda N; Nagaoka R; Sato A; Odawara H; Tozuka K; Oyama T; Takeyoshi I
Breast Cancer; 2012 Oct; 19(4):309-14. PubMed ID: 21725655
[TBL] [Abstract][Full Text] [Related]
39. A qualitative transcriptional signature to reclassify histological grade of ER-positive breast cancer patients.
Li J; Jiang W; Liang Q; Liu G; Dai Y; Zheng H; Yang J; Cai H; Zheng G
BMC Genomics; 2020 Apr; 21(1):283. PubMed ID: 32252627
[TBL] [Abstract][Full Text] [Related]
40. Association between tumor size and immunohistochemical expression of Ki-67, p53 and BCL2 in a node-negative breast cancer population selected from a breast cancer screening program.
González-Sistal A; Sánchez AB; Del Rio MC; Arias JI; Herranz M; Ruibal A
Anticancer Res; 2014 Jan; 34(1):269-73. PubMed ID: 24403473
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
